piribedil has been researched along with Parkinson Disease, Secondary in 7 studies
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, cross-over trial of the effectiveness of piribedil, procyclidine and placebo in the control of parkinsonism induced by fluphenazine decanoate was conducted in sixteen cases of chronic schizophrenia." | 5.04 | A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. ( Bradley, R; Lamb, P; Mindham, RH, 1977) |
| "Electromyographic (EMG) activity of abnormal involuntary movements and their modifications after Piribedil, a dopaminergic agonist, were analysed in patients presenting with tremor or tardive dyskinesia induced by treatment with neuroleptics." | 3.67 | EMG patterns in abnormal involuntary movements induced by neuroleptics. ( Bathien, N; Koutlidis, RM; Rondot, P, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bathien, N | 1 |
| Koutlidis, RM | 1 |
| Rondot, P | 1 |
| Smith, L | 1 |
| De Salvia, M | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Mindham, RH | 2 |
| Corsini, GU | 1 |
| Del Zompo, M | 1 |
| Spissu, A | 1 |
| Mangoni, A | 1 |
| Gessa, GL | 1 |
| Lamb, P | 1 |
| Bradley, R | 1 |
| Poirier, LJ | 1 |
| Arbuthnott, GW | 1 |
| Murray, LG | 1 |
3 trials available for piribedil and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
Parkinsonism by haloperidol and piribedil.
Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Parkinson Disease, S | 1978 |
A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
Topics: Chronic Disease; Clinical Trials as Topic; Fluphenazine; Humans; Parkinson Disease; Parkinson Diseas | 1977 |
4 other studies available for piribedil and Parkinson Disease, Secondary
| Article | Year |
|---|---|
EMG patterns in abnormal involuntary movements induced by neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Male; | 1984 |
An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiemetics; Antiparkin | 1996 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; L | 1975 |
Dopamine receptor agonists in psychiatric disease.
Topics: Bipolar Disorder; Dopamine; Humans; Parkinson Disease, Secondary; Piperazines; Piribedil; Receptors, | 1975 |